Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Siân Jones,Xiaosong Zhang,D. Williams Parsons,D. Williams Parsons,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,Hirohiko Kamiyama,Antonio Jimeno,Seung-Mo Hong,Baojin Fu,Ming Tseh Lin,Eric S. Calhoun,Mihoko Kamiyama,Kimberly Walter,Tatiana Nikolskaya,Yuri Nikolsky,James Hartigan,Douglas Smith,Manuel Hidalgo,Steven D. Leach,Alison P. Klein,Elizabeth M. Jaffee,Michael Goggins,Anirban Maitra,Anirban Maitra,Christine A. Iacobuzio-Donahue,James R. Eshleman,Scott E. Kern,Ralph H. Hruban,Rachel Karchin,Nickolas Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +37 more
Reads0
Chats0
TLDR
It is found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations, which defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors.Abstract:
There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently needed. Toward this end, we performed a comprehensive genetic analysis of 24 pancreatic cancers. We first determined the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, in these samples. Then, we searched for homozygous deletions and amplifications in the tumor DNA by using microarrays containing probes for approximately 10(6) single-nucleotide polymorphisms. We found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations. These alterations defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors. Analysis of these tumors' transcriptomes with next-generation sequencing-by-synthesis technologies provided independent evidence for the importance of these pathways and processes. Our data indicate that genetically altered core pathways and regulatory processes only become evident once the coding regions of the genome are analyzed in depth. Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis.read more
Citations
More filters
Journal ArticleDOI
The Mutational Landscape of Adenoid Cystic Carcinoma
Allen S. Ho,Kasthuri Kannan,David M. Roy,Luc G. T. Morris,Ian Ganly,Nora Katabi,Deepa Ramaswami,Logan A. Walsh,Stephanie Eng,Jason T. Huse,Jianan Zhang,Igor Dolgalev,Kety Huberman,Adriana Heguy,Agnes Viale,Marija Drobnjak,Margaret Leversha,Christine E Rice,Bhuvanesh Singh,N. Gopalakrishna Iyer,C. René Leemans,Elisabeth Bloemena,Robert L. Ferris,Raja R. Seethala,Benjamin Gross,Yupu Liang,Rileen Sinha,Luke Peng,Benjamin J. Raphael,Sevin Turcan,Yongxing Gong,Nikolaus Schultz,Seungwon Kim,Simion I. Chiosea,Jatin P. Shah,Chris Sander,William Lee,Timothy A. Chan +37 more
TL;DR: The ACC mutational landscape is determined and the exome or whole-genome sequences of 60 ACC tumor-normal pairs are reported, finding mutations in genes encoding chromatin-state regulators, suggesting that there is aberrant epigenetic regulation in ACC oncogenesis.
Journal ArticleDOI
Inhibition of Ras for cancer treatment: the search continues
TL;DR: An overview of past and ongoing strategies to inhibit oncogenic Ras in cancer is presented and genome-wide unbiased genetic screens have identified novel directions for future anti-Ras drug discovery.
Journal ArticleDOI
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Mark Sausen,Rebecca J. Leary,Siân Jones,Siân Jones,Jian Wu,Jian Wu,C. Patrick Reynolds,Xueyuan Liu,Amanda L. Blackford,Giovanni Parmigiani,Luis A. Diaz,Nickolas Papadopoulos,Bert Vogelstein,Kenneth W. Kinzler,Victor E. Velculescu,Michael D. Hogarty,Michael D. Hogarty +16 more
TL;DR: Using tumor-specific structural alterations, an approach to identify rearranged DNA fragments in sera is developed, providing personalized biomarkers for minimal residual disease detection and monitoring and provide new approaches for the management of patients with neuroblastoma.
Journal ArticleDOI
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata,Sara Akhavanfard,Serena S. David,Kathy Vernovsky,Georgiana Kuhlmann,Susan L. Boisvert,Hannah Stubbs,Ultan McDermott,Jeffrey Settleman,Eunice L. Kwak,Jeffrey W. Clark,Steven J. Isakoff,Lecia V. Sequist,Jeffrey A. Engelman,Thomas J. Lynch,Daniel A. Haber,David N. Louis,Leif W. Ellisen,Darrell R. Borger,A. John Iafrate +19 more
TL;DR: A highly sensitive multiplexed clinical assay that performs very well with nucleic acid derived from formalin fixation and paraffin embedding tissue, and tests for 120 previously described mutations in 13 cancer genes, establishes a platform for real‐time targeted genotyping that can be widely adopted.
iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns
TL;DR: PReVIously ClAssIfIed by IARC As “CARCInogenIC to humAns (gRoup 1)” And wAs deVeloped by sIx sepARAte woRkIng gRoups: phARmACeutICAls; bIologICAl Agents; ARsenIC, metAls, fIbRes, And dusts; RAdIAtIon; peRsonAl
References
More filters
Journal ArticleDOI
UCSF Chimera--a visualization system for exploratory research and analysis.
Eric F. Pettersen,Thomas D. Goddard,Conrad C. Huang,Gregory S. Couch,Daniel M. Greenblatt,Elaine C. Meng,Thomas E. Ferrin +6 more
TL;DR: Two unusual extensions are presented: Multiscale, which adds the ability to visualize large‐scale molecular assemblies such as viral coats, and Collaboratory, which allows researchers to share a Chimera session interactively despite being at separate locales.
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Mapping and quantifying mammalian transcriptomes by RNA-Seq.
TL;DR: Although >90% of uniquely mapped reads fell within known exons, the remaining data suggest new and revised gene models, including changed or additional promoters, exons and 3′ untranscribed regions, as well as new candidate microRNA precursors.
Journal ArticleDOI
Cancer statistics, 2008.
Ahmedin Jemal,Rebecca L. Siegel,Elizabeth Ward,Yongping Hao,Jiaquan Xu,Taylor Murray,Michael J. Thun +6 more
TL;DR: This report examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends.
Related Papers (5)
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
D. Williams Parsons,Siân Jones,Xiaosong Zhang,Jimmy Lin,Rebecca J. Leary,Philipp Angenendt,Parminder Mankoo,Hannah Carter,I-Mei Siu,Gary L. Gallia,Alessandro Olivi,Roger E. McLendon,B.K. Ahmed Rasheed,Stephen T. Keir,Tatiana Nikolskaya,Yuri Nikolsky,Dana A. Busam,Hanna Tekleab,Luis A. Diaz,James Hartigan,Doug R. Smith,Robert L. Strausberg,Suely Kazue Nagahashi Marie,Sueli Mieko Oba Shinjo,Hai Yan,Gregory J. Riggins,Darell D. Bigner,Rachel Karchin,Nick Papadopoulos,Giovanni Parmigiani,Bert Vogelstein,Victor E. Velculescu,Kenneth W. Kinzler +32 more
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy,Françoise Desseigne,Marc Ychou,Olivier Bouché,Rosine Guimbaud,Yves Becouarn,Antoine Adenis,Jean-Luc Raoul,Sophie Gourgou-Bourgade,Jaafar Bennouna,Jean-Baptiste Bachet,Faiza Khemissa-Akouz,Denis Péré-Vergé,Catherine Delbaldo,Eric Assenat,Bruno Chauffert,C. Montoto-Grillot,Michel Ducreux +17 more